YAP/TEAD inhibitor VT3989 is well tolerated, shows antitumor activity in advanced mesothelioma and NF2-mutant cancers

The first-in-class YAP/TEAD inhibitor VT3989 was well tolerated with durable antitumor responses in patients with advanced malignant mesothelioma and other tumors with NF2 mutations, according to results of a Phase I trial led by researchers at The University of Texas MD Anderson Cancer Center. The first-in-human study was presented today at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Leave A Comment

Your email address will not be published. Required fields are marked *